Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial - Goto, K; Goto, Y; Kubo, T (J Clin Oncol, 2023)